Investors

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and branded injectable and inhalation products.  We currently manufacture and sell over 20 branded and generic products in the U.S. and are developing a portfolio of over 20 commercial injectable and inhalation products that primarily target markets with high technical barriers to entry.

 

Press Releases

Dec 29, 2020
RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg.

Events & Presentations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

Copyright ©2021 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States